CBPO [China Biologic Products] 6-K: (Original Filing)

[FOR RELEASE June 11, 2018 China Biologic Receives CFDA Clinical Trial Approval for Human Fibrin Sealant BEIJING, China – June 11, 2018 – Fibrin Sealant is intended to be used as an adjunct to hemostasis on patients undergoing surgery in case traditional surgical techniques such as sutures, ligatures]

CBPO [China Biologic Products] 6-K: FOR RELEASE June 11, 2018 China Biologic Receives

[FOR RELEASE June 11, 2018 China Biologic Receives CFDA Clinical Trial Approval for Human Fibrin Sealant BEIJING, China – June 11, 2018 – Fibrin Sealant is intended to be used as an adjunct to hemostasis on patients undergoing surgery in case traditional surgical techniques such as sutures, ligatures]

CBPO [China Biologic Products] 6-K: (Original Filing)

[18th Floor, Jialong International Building 19 Chaoyang Park Road Chaoyang District, Beijing 100125 People’s Republic of China NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON JUNE 29, 2018 Dear Shareholder: an exempted company incorporated under the laws of the Cayman Islands Notice is]

CBPO [China Biologic Products] 6-K: 18th Floor, Jialong International Building 19 Chaoyang Park

[18th Floor, Jialong International Building 19 Chaoyang Park Road Chaoyang District, Beijing 100125 People’s Republic of China NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON JUNE 29, 2018 Dear Shareholder: an exempted company incorporated under the laws of the Cayman Islands Notice is]

CBPO [China Biologic Products] 6-K: FOR RELEASE May 4, 2018 China Biologic Reports

[FOR RELEASE May 4, 2018 China Biologic Reports Financial Results for the First Quarter of 2018 --1Q18 Total Sales Up 13.7% YoY and Non-GAAP Adjusted Net Income Up 2.1% YoY in RMB terms, or Total Sales Up 23.0% YoY to $112.5 Million and Net Income Up 5.3% YoY to $31.6 Million in USD terms-- BEIJING, ]

CBPO [China Biologic Products] 6-K: (Original Filing)

[FOR RELEASE May 4, 2018 China Biologic Reports Financial Results for the First Quarter of 2018 --1Q18 Total Sales Up 13.7% YoY and Non-GAAP Adjusted Net Income Up 2.1% YoY in RMB terms, or Total Sales Up 23.0% YoY to $112.5 Million and Net Income Up 5.3% YoY to $31.6 Million in USD terms-- BEIJING, ]

CBPO [China Biologic Products] 6-K: (Original Filing)

[FOR RELEASE April 24, 2018 China Biologic to Report First Quarter of 2018 Financial Results --Provides Preliminary First Quarter 2018 Results and Earnings Announcement Date – BEIJING, China – April 24, 2018 – The Company also provided preliminary first quarter 2018 financial highlights. Excluding th]

CBPO [China Biologic Products] 6-K: FOR RELEASE April 24, 2018 China Biologic to

[FOR RELEASE April 24, 2018 China Biologic to Report First Quarter of 2018 Financial Results --Provides Preliminary First Quarter 2018 Results and Earnings Announcement Date – BEIJING, China – April 24, 2018 – The Company also provided preliminary first quarter 2018 financial highlights. Excluding th]

CBPO [China Biologic Products] 6-K: (Original Filing)

[FOR RELEASE February 28, 2018 China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2017 --4Q17 Total Sales Up 12.2% YoY and Non-GAAP Adjusted Net Income Down 6.8% YoY in RMB terms, or Total Sales Up 16.1% YoY to $90.1 Million and Net Income Down 226.8% YoY to a net loss of]

CBPO [China Biologic Products] 6-K: FOR RELEASE February 28, 2018 China Biologic Reports

[FOR RELEASE February 28, 2018 China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2017 --4Q17 Total Sales Up 12.2% YoY and Non-GAAP Adjusted Net Income Down 6.8% YoY in RMB terms, or Total Sales Up 16.1% YoY to $90.1 Million and Net Income Down 226.8% YoY to a net loss of]

By | 2018-03-04T19:34:13+00:00 February 28th, 2018|Categories: CBPO, Chinese Stocks, Webplus ver|Tags: , , , , , |0 Comments
Skip to toolbar